Highlights Ultragenyx Pharmaceutical Inc.

Equities

RARE

US90400D1081

Real-time Estimate Cboe BZX Other stock markets 11:14:08 2024-04-29 am EDT			5-day change	1st Jan Change
44.87 ^USD	+1.42%		+2.17%	-6.65%

Apr. 22	RBC Starts Ultragenyx Pharmaceutical at Outperform, Speculative Risk With $77 Price Target, Sees 'Particularly Attractive' Risk/Reward	MT
Apr. 15	Health Care Ticks Down Amid Rotation From Rate-Sensitive Sectors -- Health Care Roundup	DJ

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Health Care Ticks Down Amid Rotation From Rate-Sensitive Sectors -- Health Care Roundup	Apr. 15	DJ
Ultragenyx Says Data From Phase 1/2 Trial of GTX-102 to Treat Angelman Syndrome Showed 'Meaningful Improvement'	Apr. 15	MT
Sector Update: Health Care Stocks Advance Premarket Monday	Apr. 15	MT
Ultragenyx Pharmaceutical Inc. Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102	Apr. 15	CI
Ultragenyx Pharmaceutical Q4 Loss Narrows, Revenue Rises; 2024 Revenue Guidance Set	Feb. 15	MT
Earnings Flash (RARE) ULTRAGENYX PHARMACEUTICAL Posts Q4 Revenue $127.4M	Feb. 15	MT
Ultragenyx Pharmaceutical Inc. Reaffirms Earnings Guidance for the Full Year 2024	Feb. 15	CI
Ultragenyx Pharmaceutical Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 15	CI
Ultragenyx Pharmaceutical Inc. Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA)	Feb. 06	CI
Ultragenyx Pharmaceutical Inc. Receives PRIME Designation from European Medicines Agency for GTX-102 for the Treatment of Angelman Syndrome	Feb. 05	CI
Ultragenyx Pharmaceutical Inc. Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease	Jan. 25	CI
Ultragenyx Pharmaceutical Reports 2023 Preliminary Revenue; Provides 2024 Guidance	Jan. 08	MT
Mereo Biopharma Group plc Provides Update on Pipeline Progress and Corporate Developments	Jan. 08	CI
Ultragenyx Pharmaceutical Inc. Provides Revenue Guidance for 2024	Jan. 07	CI
Ultragenyx's Evkeeza Recommended to National Health Service for Homozygous Familial Hypercholesterolemia Treatment	Jan. 04	MT
Ultragenyx Pharmaceutical Inc. Receives Positive Recommendation from Nice in the U.K. for Evkeeza®? V for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia	Jan. 04	CI
Ultragenyx Announces Completion of Enrollment in Global Phase 1/2 Trial of GTX-102 in Pediatric Patients with Angelman Syndrome	Jan. 03	CI
Ultragenyx Shares Rise After DOJ Says Company to Pay $6 Million to Resolve False Claims Allegations	Dec. 22	MT
Ultragenyx Pharmaceutical Gets European Approval for Familial Hypercholesterolemia Treatment for Children 5 to 11	Dec. 18	MT
Ultragenyx Receives European Commission Decision for Evkeeza® Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia	Dec. 18	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Ultragenyx Pharmaceutical Inc.

Equities

RARE

US90400D1081

Highlights

Filters